ARCELLX-ACLX-001-DDBCMA
Phase I
OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up
CARSGEN-CT053-MM-02
Phase I/II
OPEN TO ACCRUAL
Open Label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
FATE-FT576-101-MM
Phase I
OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
JNJ-MY4002-CARTINUE-LTFU
Phase N/A
OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
NOVARTIS-ADPT07A12101BCMA-CART
Phase I
OPEN TO ACCRUAL
Phase I, Open Label Study of B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients with Relapsed and/or Refractory Multiple Myeloma